Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
Adial Pharmaceuticals reported Q1 2026 financial results showing reduced net loss and provided a business update highlighting regulatory progress that may ease approval requirements for its lead drug candidate AD04 targeting Alcohol Use Disorder. The company announced a potential European partnership with Molteni Farmaceutici, strengthened intellec…